Top 8 Trials From 2021 in Breast Cancer
The Top 2021 Abstracts in Breast Cancer publication provides expert insights on groundbreaking abstracts in breast cancer, with a focus on HER2-positive breast cancer treatment that were presented at medical meetings throughout 2021.
Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®
Volume: 01
Issue: 01
Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors
The Emerging Therapeutic Approaches to Target BRAF Mutations in Solid Tumors publication covers some of the latest practice-changing advances as it relates to novel treatment strategies for patients with BRAF-mutated solid tumors.
Volume: 1
Issue: 1
SABCS 2021: Updates in HER2+ Breast Cancer
The SABCS 2021: Updates in HER2+ Breast Cancer publication provides expert insights on clinical news in HER2-positive breast cancer treatment from the 2021 San Antonio Breast Cancer Symposium.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
Volume: 01
Issue: 01
2021 Year in Review: HER2+ Breast Cancer
The 2021 Year in Review: HER2+ Breast Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in HER2-positive breast cancer in 2021, along with expert insights in article and video format.
Volume: 1
Issue: 1
My Treatment Approach: Advanced Ovarian Cancer
The My Treatment Approach: Advanced Ovarian Cancer publication covers some of the latest practice-changing advances in the treatment for patients with advanced ovarian cancer following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.
Volume: 1
Issue: 1
2021 Year in Review: Updates in Biomarker-Driven Lung Cancer
The 2021 Year in Review: Updates in Biomarker-Driven Lung Cancer is the digital version of a print publication encompasses some of the biggest data that have read out in bimarker-driven lung cancer in 2021, along with expert insights in article and video format.
Funding From Daiichi Sankyo/Content Developed Independently by OncLive
Volume: 1
Issue: 1
My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD
The My Treatment Approach: Optimal Second- and Third-Line Treatment Options of cGVHD publication covers some of the latest and practice-changing advances in the treatment for patients with chronic graft-vs-host disease following recent regulatory decisions and data read outs from pivotal clinical trials, as well as expert insights on how they approach therapy on an individualized basis.
Volume: 1
Issue: 1